Binosto

Binosto

alendronic acid

Manufacturer:

SwissCo Services AG

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Alendronate Na
Indications/Uses
Postmenopausal osteoporosis. Reduces risk of vertebral & hip fractures.
Dosage/Direction for Use
Administration
Should be taken on an empty stomach.
Contraindications
Hypersensitivity. Abnormalities of the oesophagus & other factors which delay oesophageal emptying eg, stricture or achalasia. Inability to stand or sit upright for at least 30 min. Hypocalcaemia.
Special Precautions
Active upper GI problems eg, dysphagia, oesophageal disease, gastritis, duodenitis, ulcers or recent history (1 yr) of major GI disease eg, peptic ulcer or active GI bleeding or surgery of the upper GIT other than pyloroplasty. Potential risks in patients w/ Barrett's oesophagus. Discontinue use if signs or symptoms of oesophageal irritation occurs. Osteonecrosis of the jaw associated w/ tooth extraction &/or local infection (including osteomyelitis). Dental examination w/ appropriate preventive dentistry should be considered prior to treatment in patients w/ poor dental status & avoid invasive dental procedures. Maintain good oral hygiene, receive routine dental check-ups & report any oral symptoms (eg, dental mobility, pain or swelling). Bone, joint, &/or muscle pain. Atypical subtrochanteric & diaphyseal femoral fractures have been reported in patients receiving long-term treatment for osteoporosis. Possible risk factors for osteonecrosis of the external auditory canal include steroid use & chemotherapy &/or local risk factors eg, infection or trauma. Hypocalcaemia must be corrected before initiating therapy. Adequate Ca & vit D intake particularly in patients receiving glucocorticoids. May affect the ability to drive or operate machinery. Patients on a controlled Na diet. Not recommended for patients w/ renal impairment (GFR <35 mL/min). Do not use during pregnancy & lactation. Not recommended for use in Childn <18 yr.
Adverse Reactions
Musculoskeletal (bone, muscle or joint) pain. Headache, dizziness; vertigo; abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer, dysphagia, abdominal distension, acid regurgitation; alopecia, pruritus; joint swelling; asthenia, peripheral oedema.
Drug Interactions
May interfere absorption w/ food & beverages (including mineral water), Ca supplements, antacids & some oral medicinal products. Caution in concomitant w/ NSAIDs.
ATC Classification
M05BA04 - alendronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Presentation/Packing
Form
Binosto effervescent tab 70 mg
Packing/Price
12's;4's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in